---
title: "Imac | 10-Q: FY2025 Q3 Revenue: USD 21.22 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/270067806.md"
datetime: "2025-12-17T22:01:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270067806.md)
  - [en](https://longbridge.com/en/news/270067806.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270067806.md)
generator: "portal-rs"
---

# Imac | 10-Q: FY2025 Q3 Revenue: USD 21.22 K

Revenue: As of FY2025 Q3, the actual value is USD 21.22 K.

EPS: As of FY2025 Q3, the actual value is USD -1.15.

EBIT: As of FY2025 Q3, the actual value is USD -2.135 M.

### Segment Revenue

-   For the three months ended September 30, 2025, IMAC Holdings, Inc. reported net revenue of $0.02 million, compared to $0.06 million for the same period in 2024.
-   For the nine months ended September 30, 2025, net revenue was $0.02 million, compared to $0.07 million for the same period in 2024.

### Operational Metrics

-   The company reported a net loss of $3.1 million for the three months ended September 30, 2025, compared to a net loss of $2.2 million for the same period in 2024.
-   For the nine months ended September 30, 2025, the net loss was $7.4 million, compared to $4.0 million for the same period in 2024.
-   Operating expenses for the three months ended September 30, 2025, were $2.5 million, up from $1.9 million in the same period in 2024.
-   Operating expenses for the nine months ended September 30, 2025, were $6.4 million, compared to $3.7 million for the same period in 2024.

### Cash Flow

-   Net cash used in operating activities for the nine months ended September 30, 2025, was $3.8 million, compared to $2.0 million for the same period in 2024.
-   Net cash provided by financing activities during the nine months ended September 30, 2025, was $3.3 million, primarily from the sale of common stock and issuance of promissory notes.

### Unique Metrics

-   The company recognized an impairment loss of $0.75 million on laboratory equipment during the three months ended September 30, 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: IMAC Holdings, Inc. plans to focus on its precision medicine in cancer treatment, leveraging its RPPA technology platform to support oncology clinical treatment decisions and biopharmaceutical drug development.
-   **Non-Core Business**: The company has discontinued operations related to patient care at all locations as of December 31, 2023, and is focusing on its laboratory capabilities acquired from Theralink Technologies, Inc.
-   **Priority**: The company aims to raise additional capital to fund future operations and mitigate substantial doubt about its ability to continue as a going concern.

### Related Stocks

- [BACK.US](https://longbridge.com/en/quote/BACK.US.md)

## Related News & Research

- [ROI-Oil's new problem isn't supply. It's logistics: Bousso](https://longbridge.com/en/news/300903866.md)
- [‘One for the Kids,’ Says Top Investor About SpaceX Stock](https://longbridge.com/en/news/300955937.md)
- [Microsoft Could Be SpaceX's Next Big AI Customer: Bernstein Sees AI Revenue Surging Nearly 500%](https://longbridge.com/en/news/300953883.md)
- [Microsoft's blazing stock comeback isn't even close to being over, analyst says](https://longbridge.com/en/news/300955443.md)
- [Michael Burry Raises Red Flag on Oracle’s $664B Backlog and AI Spending: ‘The Customer Is Now the Lender’](https://longbridge.com/en/news/300913488.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**